The latest news from MDedge Hematology/Oncology: In this episode: MRI reliably identifies significant prostate cancer * Original MDedge article (https://bit.ly/3hgKT1h) * PROMIS analysis (https://bit.ly/3fLOiEN) Drug-drug interactions to avoid in patients with GI cancer * Original MDedge article (https://bit.ly/39eHi0G) ctDNA clearance tracks with PFS in NSCLC subtype * Original MDedge article (https://bit.ly/3eJKm6o) * Abstract from AACR 2020 (https://bit.ly/30uQQ3R) * TATTON results in The Lancet Oncology (https://bit.ly/3jq1L7J) COVID-19 symptoms can linger for months * Original MDedge article (https://bit.ly/3eNREG0) * JAMA research letter (https://bit.ly/2WFS3UW) For more MDedge Podcasts go to https://mdedge.com/podcasts/ Email the show: [email protected] Interact with us on Twitter: @MDedgeHemOnc

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related